pibrentasvir

February 7, 2017February 7, 2017

Hepatitis C Therapy Candidate Granted Priority Review from Health Canada

Hepatitis C, News

A potential new drug being developed for the treatment of chronic hepatitis C received priority review from Health Canada. This means that the compound may be reviewed in advance of ... Read more

January 26, 2017January 26, 2017

Marketing Application for HCV Treatment Candidate G/P Validated in Europe

Hepatitis C, News

AbbVie’s marketing authorization application (MAA) for its investigational drug glecaprevir/pibrentasvir (G/P), developed as a treatment for chronic hepatitis C virus (HCV) genotypes 1 to 6, has been validated by the European ... Read more

January 12, 2017January 12, 2017

AbbVie’s One-Pill Combo Therapy Shows Promise for Hepatitis C in Japanese Trial

Hepatitis C, News

AbbVie’s new hepatitis C treatment candidate, a one tablet combination of the investigational drugs glecaprevir and pibrentasvir, harnessed the infection in all patients who completed a Japanese study. The treatment, ... Read more